Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2536 to 2550 of 8915 results

  1. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Mexiletine hydrochloride for treating myotonia in children and adolescents with myotonic disorders [TS ID 11978]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 6 months to 11 [TSID11806]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Imbio CT lung texture analysis for identifying interstitial lung disease (MT618) (MIB272)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  7. Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  9. Mepolizumab for treating chronic obstructive pulmonary disease with eosinophil-associated exacerbations TSID12019

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

    Quality standard
    In development

  11. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

    Quality standard
    In development

  12. Ponatinib for treating recurrent or refractory chronic myeloid leukaemia in people 1 to 17 years when another tyrosine kinase inhibitor is unsuitable [TSID12041]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

    NICE guideline
    In development

  15. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

    Technology appraisal guidance
    In development